Skip to main content
Erschienen in:

Open Access 15.02.2022 | Commentary

Time for a Standardized Common Femoral Artery Classification System

verfasst von: Thomas Zeller

Erschienen in: CardioVascular and Interventional Radiology | Ausgabe 4/2022

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
During the last decade, interventional therapy of common femoral artery (CFA) lesions has become an attractive alternative to the open surgical reconstruction by means of endarterectomy with or without patch plastic. However, prospective comparative data between endovascular treatment and surgery are still rare mainly comparing stenting with TEA [1]. CFA lesions may differ regarding location (exclusive CFA involvement vs. extension into the femoral bifurcation or external iliac artery) and morphology (e.g., degree of calcification). Therefore, there is a need for a standardized classification system to allow the comparison of published data as well as to identify treatment strategies that fit best individual lesion characteristics.
The modified coronary Medina classification proposed by Bonvini et al. is limited by considering only the anatomical lesion location and lesion extension [2]. The Azema classification included information about lesion morphology defining four types of lesion locations [3] but the degree of calcification and the severity of the lesion (stenosis vs. occlusion) were not part of the classification system. However, these missing parameters are potential predictors for acute treatment success and durability of the revascularization procedure.
In the present study, Rabellino et al. modified the Azema classification in a very practical way [4]: Previous Type IV lesions defined as bypass stenotic lesions were excluded in order to limit the new classification to native artery atherosclerotic lesions. Hence, Type I-III lesions remained the same. Type IV lesions in the new classification include lesions extending either from the external iliac artery (EIA) or common iliac artery (CIA) into the CFA and affecting its bifurcation.
Three additional lesion sub-characteristics were added for a more detailed lesion description of the four types of lesions: In Type III and IV lesions, it was specified which branch of the femoral bifurcation is involved. If only the superficial femoral artery (SFA) is affected, this was classified with an “S.” If only the deep femoral artery (DFA) was involved, a “D” was given, and if both branches were involved, it was classified as a “B” for both. As such, a Type III lesion starting at the CFA and extending to both the branches was denominated as a “TYPE III B” lesion. A further differentiation involves stenotic (“S”) versus occlusive (“O”) lesions. Finally, vascular calcium assessment was made by fluoroscopy or by computed tomography and added to the classification in heavy calcium burden “H” or with mild to moderate calcium burden “M.” Back to the example of a Type III B lesion with occlusive disease and heavy calcium burden, the lesion would be classified as a Type III B, O, H lesion.
Classifying CFA lesions in this proposed fashion in upcoming studies will allow a better comparison of acute and potentially long-term outcomes. Besides the small sample size, the main limitation of the study is the unusual definition of primary patency (“time free from more than 50% restenosis following index treatment”). This makes it impossible to compare the primary study end point of the Rabellino with historic studies and limits the prediction of long-term treatment success stratified to the proposed lesion characteristics.
In summary, the new CFA lesion classification proposed by Rabellino et al. should be applied to all upcoming studies for improving study comparability and identification of potential predictors of acute and long-term treatment success for each individual treatment modality.

Acknowledgements

None.

Declarations

Conflict of interest

Honoraria received from Abbott Vascular, BIBA Medical, Biotronik, Boston Scientific Corp., Cook Medical, Efemoral, Gore & Associates, Medtronic, Philips-Spectranetics, Shockwave, Veryan. Consulted for Boston Scientific Corp., CSI, Gore & Associates, Medtronic, Veryan, Philips-Intact Vascular, Shockwave, Bayer, Vesper Medical, VentureMed, ANT. Institutional Grants for research, clinical trial, or drug studies received from Bard Peripheral Vascular, Veryan, Biotronik, Cook Medical, Gore & Associates, Medtronic, Philips, Terumo, TriReme, Shockwave, Med Alliance, Intact Vascular, B. Braun; CSI, Boston Scientific, University of Jena, Pluristem, Philips, PQ Bypass. Common stock: QT Medical.

Ethical Approval

For this commentary, formal consent is not required.
For this commentary, informed consent is not required.
For this commentary, consent for publication is not required.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

e.Med Radiologie

Kombi-Abonnement

Mit e.Med Radiologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Radiologie, den Premium-Inhalten der radiologischen Fachzeitschriften, inklusive einer gedruckten Radiologie-Zeitschrift Ihrer Wahl.

Literatur
2.
Zurück zum Zitat Bonvini RF, Rastan A, Sixt S, Noory E, Schwarz T, Frank U, et al. Endovascular treatment of common femoral artery disease: medium-term outcomes of 360 consecutive procedures. J Am Coll Cardiol. 2011;58(8):792–8.CrossRef Bonvini RF, Rastan A, Sixt S, Noory E, Schwarz T, Frank U, et al. Endovascular treatment of common femoral artery disease: medium-term outcomes of 360 consecutive procedures. J Am Coll Cardiol. 2011;58(8):792–8.CrossRef
Metadaten
Titel
Time for a Standardized Common Femoral Artery Classification System
verfasst von
Thomas Zeller
Publikationsdatum
15.02.2022
Verlag
Springer US
Erschienen in
CardioVascular and Interventional Radiology / Ausgabe 4/2022
Print ISSN: 0174-1551
Elektronische ISSN: 1432-086X
DOI
https://doi.org/10.1007/s00270-021-03034-6

Neu im Fachgebiet Radiologie

KI-gestütztes Mammografiescreening überzeugt im Praxistest

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

Stumme Schlaganfälle − ein häufiger Nebenbefund im Kopf-CT?

In 4% der in der Notfallambulanz initiierten zerebralen Bildgebung sind „alte“ Schlaganfälle zu erkennen. Gar nicht so selten handelt es sich laut einer aktuellen Studie dabei um unbemerkte Insulte. Bietet sich hier womöglich die Chance auf ein effektives opportunistisches Screening?

Die elektronische Patientenakte kommt: Das sollten Sie jetzt wissen

Am 15. Januar geht die „ePA für alle“ zunächst in den Modellregionen an den Start. Doch schon bald soll sie in allen Praxen zum Einsatz kommen. Was ist jetzt zu tun? Was müssen Sie wissen? Wir geben in einem FAQ Antworten auf 21 Fragen.

Stören weiße Wände und viel Licht die Bildqualitätskontrolle?

Wenn es darum geht, die technische Qualität eines Mammogramms zu beurteilen, könnten graue Wandfarbe und reduzierte Beleuchtung im Bildgebungsraum von Vorteil sein. Darauf deuten zumindest Ergebnisse einer kleinen Studie hin. 

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.